A Study to Evaluate the Safety of Concurrent Durvalumab With CRT Followed by Durvalumab for Chinese Unresectable Stage III NSCLC

Condition:   Unresectable Stage III NSCLC Interventions:   Drug: Durvalumab;   Drug: Cisplatin/ Etoposide;   Drug: Carboplatin/ Paclitaxel;   Drug: Pemetrexed/ Cisplatin;   Drug: Pemetrexed/ Carboplatin;   Radiation: Radiation Sponsor:   Shandong Cancer Hospital and Institute Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials